Ultime notizie per Tyra Biosciences (NASDAQ:TYRA) Azioni

Tyra Biosciences

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Tyra Biosciences Inc

Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $1.17 by 4.27 percent. The company reported quarterly sales of $3.17 billion which missed the analyst consensus estimate of $3.24 billion by 1.90 percent. This is a 0.38 percent increase over sales of $3.16 billion the same period last year.

Earnings

News

HSIC

Henry Schein Q3 2024 Adj EPS $1.22 Beats $1.17 Estimate, Sales $3.17B Miss $3.24B Estimate

Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) reported quarterly sales of $3.852 billion which missed the analyst consensus estimate of $4.060 billion by 5.13 percent. This is a 1.16 percent decrease over sales of $3.897 billion the same period last year.

Earnings Misses

TRGP

Targa Resources Q3 Sales $3.852B Miss $4.060B Estimate

Stifel analyst Paul Matteis upgrades Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) from Hold to Buy and raises the price target from $25 to $36.

Upgrades

Price Target

Analyst Ratings

ALKS

Stifel Upgrades Alkermes to Buy, Raises Price Target to $36

Vestas Wind Systems (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWDRY#OTC">VWDRY</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.09 by 44.44 percent. The company reported quarterly sales of $5.690 billion which beat the analyst consensus estimate of $5.512 billion by 3.23 percent. This is a 20.09 percent increase over sales of $4.738 billion the same period last year.

Earnings Beats

VWDRY

Vestas Wind Systems Q3 2024 GAAP EPS $0.05 Misses $0.09 Estimate, Sales $5.690B Beat $5.512B Estimate

Louisiana-Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $0.88 by 38.64 percent. This is a 24.69 percent decrease over earnings of $1.62 per share from the same period last year. The company reported quarterly sales of $722.00 million which beat the analyst consensus estimate of $680.23 million by 6.14 percent. This is a 0.82 percent decrease over sales of $728.00 million the same period last year.

Louisiana-Pacific Q3 2024 Adj EPS $1.22 Beats $0.88 Estimate, Sales $722.00M Beat $680.23M Estimate

DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.03 by 14.56 percent. This is a 28.26 percent increase over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $3.192 billion which missed the analyst consensus estimate of $3.204 billion by 0.38 percent. This is a 4.38 percent increase over sales of $3.058 billion the same period last year.

DuPont Q3 2024 Adj. EPS $1.18 Beats $1.03 Estimate, Sales $3.192B Miss $3.204B Estimate

B. Riley Securities analyst Jeff Van Sinderen initiates coverage on MSA Safety (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSA#NYSE">MSA</a>) with a Buy rating and announces Price Target of $200.

Initiation

B. Riley Securities Initiates Coverage On MSA Safety with Buy Rating, Announces Price Target of $200

Anglo American (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAUKF#OTC">AAUKF</a>) has agreed to sell its 33.3% stake in the Jellinbah Group to Zashvin for $1.1 billion. Per the plan laid out <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/38826363/anglo-american-expedites-plan-to-divest-de-beers-other-assets-after-rebuffing-bhp-takeover-bid" rel="noreferrer noopener">earlier this year</a>, the company is focusing on <a target="_blank" href="https://www.benzinga.com/topic/copper" rel="noreferrer noopener">copper</a>, iron ore, and crop nutrients.
The joint venture holds a 70% interest in two major metallurgical coal mines in Queensland: Jellinbah East and Lake Vermont. Anglo did not operate these mines nor market their output.
"We are making excellent progress with our simplification of Anglo American to create an exciting and differentiated investment proposition focused on our world-class copper, premium iron ore, and crop nutrients assets &#8211; all future-enabling products," <a target="_blank" href="https://www.angloamerican.com/media/press-releases/2024/04-11-2024" rel="noreferrer noopener">said</a> CEO Duncan Wanblad.
Despite its unpopular status due to environmental concerns, coal remains an important commodity. A recent <a target="_blank" href="https://www.benzinga.com/news/24/11/41710410/australian-breakthrough-extends-use-for-coal-powered-plants-helps-shift-to-renewables" rel="noreferrer noopener">Australian achievement</a> in shutting down and restarting a power plant shows that its decline could be much more gradual than anticipated.
Still, Anglo American is set on divesting its remaining coal assets, aiming to net between $5b and $6b. Talks are underway with potential buyers, including Peabody (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>), Yancoal (OTCPK: YACAF), and Glencore (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLNCY#OTC">GLNCY</a>) &#8211; which has decided against <a target="_blank" href="https://www.benzinga.com/m-a/24/08/40216672/glencore-votes-against-spinning-off-coal-remains-open-to-more-acquisitions" rel="noreferrer noopener">spinning off its coal business</a>.
"This highly cash generative and much higher margin portfolio will offer greater resilience through cycles and the benefit of significant high-quality and well-sequenced growth options," Wanblad noted regarding the process.
Anglo American's broader restructuring efforts were announced earlier this year amidst an attempted takeover by BHP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>). Besides coal, the plan involved shedding even South African De Beers, the world's largest diamond producer.
However, challenges in the diamond market have made a sale less feasible, with Anglo preferring to wait for market recovery to optimize value from its "crown jewel." A complicated situation with South African assets is often quoted as one of the biggest hurdles in BHP's <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/39068033/time-runs-out-for-bhp-deal-49-billion-acquisition-of-anglo-american-proves-too-complex-to-solve" rel="noreferrer noopener">failed bid</a>.
Although a recent comment from BHP's chairman signaled that both parties have moved on, the miner quickly retraced that comment. The mandatory standstill on offers expires on November 29, with Anglo's market cap currently at approximately $42 billion—$47 billion below BHP's final $49b bid in May.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/11/41722178/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan" target="_blank" rel="noreferrer noopener">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a></li>
</ul>
Photo via Company

Large Cap

Commodities

Asset Sales

AAUKF

GLNCY

YACAF

Anglo American Offloads $1.1 Billion Coal Stake, Proceeds With Restructuring

Dr Reddy's Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $84.03 by 99.79 percent. This is a 14.29 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $957.00 million which missed the analyst consensus estimate of $76.49 billion by 98.75 percent. This is a 16.57 percent increase over sales of $821.00 million the same period last year.

Dr Reddy's Laboratories Q2 2025 GAAP EPS $0.18 Compared To $0.21 YoY, Sales $957.00M Compared To $821M YoY

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) with a Overweight rating and announces Price Target of $75.

Piper Sandler Initiates Coverage On Upstream Bio with Overweight Rating, Announces Price Target of $75

Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) expanded its multi-year partnership with Telia Company to advance Telia&#8217;s modernization and transformation of telecom and cloud infrastructure <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41737175/broadcom-and-telia-announce-expanded-partnership-to-further-transform-telco-and-cloud-infrastructu" rel="noreferrer noopener">using VMware&#8217;s product portfolio</a>.
The expanded use of VMware&#8217;s cloud-native architecture will advance Telia&#8217;s automation efforts across network workloads and extend its cloud-native capabilities for key assets.
Krish Prasad, SVP and general manager, VMware Cloud Foundation Division, Broadcom, said, &#8220;We are delighted to enable Telia to continue serving its customers with this VMware software-based platform that includes the needed network and infrastructure orchestration, automation and scale.&#8221;
In addition, Broadcom disclosed significant enhancements to its VeloCloud product line and introduced a new partner program aimed at helping enterprises better support AI and non-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41737271/broadcom-unveils-velorain-an-industry-first-for-robust-ai-networking-beyond-the-data-center" rel="noreferrer noopener">AI workloads and enhance connectivity</a>.
Broadcom&#8217;s latest advancements include the launch of VeloRAIN, an AI/ML-powered architecture designed to boost the performance and security of distributed AI workloads.
It also introduced the high-capacity VeloCloud Edge 4100 and 5100 appliances, which support up to 100Gbps for large enterprises. Additionally, the new Titan Partner Program will help VeloCloud Managed Service Providers grow as enterprise AI adoption accelerates.
Sanjay Uppal, vice president and general manager, VeloCloud Division, Broadcom, stated, &#8220;By harnessing the advanced capabilities of VeloRAIN, AI workloads from distributed inferencing and agentic peer-to-peer applications to upstream heavy RAG transactions will see improved application-based QoE and security across all endpoints of the enterprise.&#8221;
Apart from this, at VMware Explore 2024 in Barcelona, the company disclosed expanded VMware Cloud Foundation (VCF) Advanced Services, new ecosystem <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41737281/vmware-cloud-foundation-delivers-a-private-cloud-platform-to-accelerate-customers-ai-sovereignty-a" rel="noreferrer noopener">partnerships, and modernization programs</a>.
These initiatives aim to accelerate generative AI application development, enhance cybersecurity, and support sovereign cloud adoption.
Krish Prasad, senior vice president and general manager, VCF Division at Broadcom, commented, &#8220;Through a private cloud platform and portfolio of Advanced Services that are ubiquitous, flexible and secure, we are unlocking the promise of AI in the enterprise, delivering new levels of organizational resilience, and supporting the privacy and digital sovereignty demands of customers around the world.&#8221;
Investors can gain exposure to the stock via Direxion Daily AVGO Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVL#NASDAQ">AVL</a>) &nbsp;and&nbsp;Columbia Semiconductor and Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMI#NYSE">SEMI</a>).
Price Action: AVGO shares are up 0.49% at $169.38 premarket at the last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41609022/openai-chooses-broadcom-for-ai-interface-chip-development" target="_blank" rel="noreferrer noopener">OpenAI Chooses Broadcom For AI Interface Chip Development</a></li>
</ul>

Equities

Contracts

AVGO

SEMI

Broadcom Powers Telia's Modernization with VMware, Launches AI-Driven VeloRAIN & More

Piper Sandler analyst Edward Tenthoff initiates coverage on Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) with a Overweight rating and announces Price Target of $18.

CAMP

Piper Sandler Initiates Coverage On Camp4 Therapeutics with Overweight Rating, Announces Price Target of $18

BitFuFu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) reported quarterly losses of $(0.03) per share. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $90.34 million in sales this quarter. This is a 47.57 percent increase over sales of $61.22 million the same period last year.

FUFU

BitFuFu Q3 EPS $(0.03) Down From $(0.02) YoY, Sales $90.34M Up From $61.22M YoY

Shares of Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">above consensus estimates</a>.
Revenue increased 5% year over year to $3.07 billion, beating the consensus of $3.05 billion. Adjusted EPS of 77 cents surpassed the street view of 68 cents.
Palantir Technologies shares rose 12.9% to $46.75 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) gained 69.5% to $2.00 in pre-market trading after jumping around 269% on Monday.</li>
<li>Bionomics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) rose 67.6% to $0.3219 in pre-market trading. Bionomics received milestone payment of AUS$1 million from Carina Biotech for BNC101 partnered legacy oncology program.</li>
<li>Avalon GloboCare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALBT#NASDAQ">ALBT</a>) shares surged 42.4% to $3.19 in pre-market trading after dipping 24% on Monday.</li>
<li>QuinStreet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) climbed 29.8% to $26.22 in pre-market trading after the company posted upbeat quarterly results and raised its FY25 sales outlook.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) gained 26.1% to $87.83 in pre-market trading after the company announced better-than-expected quarterly results.</li>
<li>Zyversa Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares rose 15.3% to $2.10 in pre-market trading after falling 5% on Monday.</li>
<li>Vimeo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) gained 15.2% to $5.54 in pre-market trading after the company posted upbeat quarterly results.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 12.6% to $3.12 in pre-market trading.</li>
<li>Alarum Technologies Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) gained 16.6% to $14.39 in pre-market trading.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 11.9% to $0.0225 in pre-market trading after the company announced update and extension of pending offer to exchange.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) shares tumbled 38.8% to $3.64 in pre-market trading following weak quarterly sales.</li>
<li>Verrica Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares fell 31.4% to $0.98 in pre-market trading after the company posted downbeat quarterly results.</li>
<li>Trio Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NYSE">TPET</a>) dipped 24.8% to $0.0960 in pre-market trading after the company announced a 1-for-20 reverse stock split.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares fell 19.4% to $2.10 in pre-market trading after the company reported weak third-quarter sales.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) declined 18% to $42.55 in pre-market trading following soft fourth-quarter guidance.</li>
<li>Nft Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MI#NYSE">MI</a>) shares dipped 16.1% to $7.50 in pre-market trading after gaining 9% on Monday.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) fell 16.2% to $5.66 in pre-market trading after surging more than 40% on Monday.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) fell 15.8% to $103.89 in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and announced it intends to temporarily reduce its quarterly dividend.</li>
<li>Altice USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) fell 14.3% to $2.22 in pre-market trading after the company reported weak third-quarter financial results.</li>
<li>Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) fell 10.3% to $13.55 in pre-market trading after the company posted weak quarterly sales and lowered FY24 sales forecast.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41735761/dow-tumbles-250-points-as-investors-brace-for-high-stakes-presidential-election-greed-index-enters-">Dow Tumbles 250 Points As Investors Brace For High-Stakes Presidential Election: Greed Index Enters &#8216;Fear&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALAB

ALAR

ALBT

ATUS

BNOX

ELAB

LSCC

NVTS

PLTR

QNST

SPPL

TCMD

TPET

VMEO

VRCA

VSTE

ZVSA

Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

SBSW

Sibanye Stillwater Q3 Adjusted EBITDA $184M, Up 9% Year-On-Year

Legal

NFLX

Reuters Reported France's PNF Financial Prosecutor Body Has Carried Out Searches Today At Netflix France, Amsterdam Offices, Citing Judicial Source

Phunware Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) experienced a significant surge in its stock price, climbing 10.27% during pre-market trading on Tuesday, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. 
What Happened: The stock&#8217;s rise occurred just one day before the U.S. Elections. This increase comes as the company remains linked to former President Donald Trump, having managed his 2020 reelection campaign&#8217;s mobile app.
On Friday, Phunware also revealed that Troy Reisner, the<a href="https://www.benzinga.com/markets/equities/24/11/41712003/trump-linked-phunwares-leadership-shuffle-continues-cfo-joins-ceo-in-exit-queue"> Chief Financial Officer</a>, intends to resign between Nov. 15 and Nov. 30. The company emphasized that Reisner&#8217;s departure is not due to any disagreements over business operations or financial practices. A search for a new CFO is underway. Post the announcement, on Monday, PHUN dropped by 10% during pre-market.
During this transition, Interim CEO Stephen Chen will collaborate with Brendhan Botkin, Vice President of Accounting and Financial Reporting, to oversee the roles of principal financial officer and principal accounting officer. Last month, Phunware announced the<a href="https://www.benzinga.com/news/24/10/41521091/trump-linked-phunware-stock-falls-as-ceo-exits-what-you-need-to-know"> resignation of CEO</a> Michael Snavely, with Stephen Chen assuming the role of interim CEO.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41734592/palantir-trump-media-hims-hers-health-nxp-semiconductors-and-tesla-why-these-5-stocks-are-on-inv?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">PLTR, DJT, HIMS, NXPI, TSLA: Top 5 Trending Stocks Today</a>
Why It Matters: Phunware&#8217;s stock has been subject to fluctuations, often influenced by its ties to Trump-related ventures. On Oct. 15, Phunware&#8217;s shares surged amid market momentum and its association with <a href="https://www.benzinga.com/news/24/10/41339350/phunware-stock-skyrockets-amid-trump-association-and-market-momentum-whats-going-on">Trump Media &amp; Technology Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), which launched its Truth+ streaming service. The platform is set to expand with an iOS app and availability on platforms like Apple TV and Amazon Fire.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734897/elon-musks-doge-department-mention-gives-dogecoin-boost-to-top-of-daily-gainers-memecoin-s?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s &#8216;DOGE&#8217; Department Mention Gives Dogecoin Boost To Top Of Daily Gainers: Memecoin Spikes 6%</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

General

PHUN

Trump-Linked Phunware Stock Is Surging 10% In Pre-Market: What's Going On?

Guidance

Health Care

Fresenius Medical Care Also Reconfirms Its Targets To Achieve An Operating Income Margin Of 10%-14% By 2025

Fresenius Medical Care Confirms Its Outlook For Fiscal 2024 And Expects Revenue To Grow By A Low- To Mid-single Digit Percent Rate, With Operating Income To Grow By 16%-18% Versus Prior Guidance Of Growth By A Mid- To High-teens Percent Rate

Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.35 by 108.57 percent. This is a 28.07 percent increase over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $4.76 billion which missed the analyst consensus estimate of $4.89 billion by 2.67 percent. This is a 3.57 percent decrease over sales of $4.94 billion the same period last year.

Fresenius Medical Care Q3 2024 Adj EPS €0.73 May Not Be Comparable To €0.35 Estimate, Sales €4.76B Miss €4.89B Estimate

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Supernus Pharmaceuticals (SUPN – Research Report) an...

Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN) and Tyra Bioscience (TYRA)

Tyra raised to buy by BofA ahead of TYRA-300 data readout

Tyra Biosciences (TYRA) announced clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial – mUC – cancer from its ongoin...

Tyra Biosciences' TYRA-300 shows anti-tumor activity in proof-of-concept trial

Tyra Bioscience ( ($TYRA) ) has provided an announcement. Tyra Biosciences announced promising interim clinical results for TYRA-300 in metastatic ...

Tyra Bioscience Shows Promise with TYRA-300 Results

In a report released today, Robert Driscoll from Wedbush maintained a Buy rating on Tyra Bioscience (TYRA – Research Report), with a price target o...

Tyra Bioscience (TYRA) Gets a Buy from Wedbush

Tyra stock plunges 17% amid TYRA-300 study data release

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: A U.S. judge has blocked the proposed ...

Judge blocks Tapestry-Capri deal, Centene reports Q3 beat: Morning Buzz

H.C. Wainwright raised the firm's price target on Tyra Biosciences (TYRA) to $32 from $30 and keeps a Buy rating on the shares. The firm says TYRA-...

Tyra Biosciences price target raised to $32 from $30 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Tyra Bioscience (TYRA – Research Report) today and set a price target of $32.00....

Buy Recommendation for Tyra Bioscience Based on Promising Clinical Data and Safety Profile of TYRA-300

Tyra Biosciences (TYRA) announced that the FDA cleared its Investigational New Drug application for Tyra-300 allowing the company to proceed with a...

Tyra Biosciences granted IND clearance from FDA for Phase 2 study of Tyra-300

AAPL

BYON

CPRI

DBRG

DECK

JOBY

MSFT

NYCB

PIPR

RLAY

SNYNF

SUPN

TMHC

TMUS

TSLA

TYRA

Press Releases

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)

Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights

Small Cap

TYRA Investors Have Opportunity to Join Tyra Biosciences, Inc. Securities Fraud Investigation with the Schall Law Firm

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Comments

Tyra Biosciences

Notizie

Ultime notizie per Tyra Biosciences (NASDAQ:TYRA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO